Poststroke cognitive impairment: diagnosis and treatment
https://doi.org/10.14412/2074-2711-2018-2-88-94
Abstract
The socially significant problems in patients with prior stroke include post-stroke cognitive impairment (PCI), the prevalence of which is high (from 24 to 70%). The causes of disability in these patients are that the role of cognitive impairment is often underestimated and attention is paid only to motor defects. The pathogenesis of PCI may include not only vascular, but also neurodegenerative (due to Alzheimer's disease) mechanisms of brain damage. The diagnosis of early PCI is of great practical importance, as it is most effective to treat mild PCI. The paper considers current approaches to preventing and treating PCI. The authors give their own experience in treating a patient with moderate PCI.
About the Authors
V. A. GolovachevaRussian Federation
Contact: Veronika Aleksandrovna Golovacheva
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Moscow 119021
A. A. Golovacheva
Russian Federation
Department of Nervous System Diseases and Neurosurgery, Faculty of General Medicine
11, Rossolimo St., Moscow 119021
References
1. Strong K, Mathers C, Bonita R. Preventing stroke: saving lives around the world. Lancet Neurol. 2007 Feb;6(2):182-7.
2. Towfighi A, Saver JL. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke. 2011 Aug;42(8):2351-5. doi: 10.1161/STROKEAHA.111.621904. Epub 2011 Jul 21.
3. Mackay J, Mensah GA, editors. The atlas of heart disease and stroke. Geneva: World Health Organization; 2004.
4. Gusev EI, Skvortsova VI, Stakhovskaya LV. Epidemiology of stroke in Russia. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2003;(8):4-9. (In Russ.).
5. Gusev EI, Martynov MYu, Kamchatnov PR. Ischemic stroke. Current state of the problem. Doktor.ru. 2013;(5):2-7. (In Russ.).
6. Shakhparonova NV, Kadykov AS. Post-stroke cognitive impairment. Medical correction with citicoline (Ceraxon). Nervnye bolezni. 2011;(2):16-9. (In Russ.).
7. Gutiеrrez Pеrez C, Savborg M, Pahlman U, et al. High frequency of cognitive dysfunction before stroke among older people. Int J Geriatr Psychiatry. 2011 Jun;26(6):622-9. doi: 10.1002/gps.2573. Epub 2010 Oct 4.
8. Douiri A, Rudd AG, Wolfe CD. Prevalence of poststroke cognitive impairment: South London Stroke Register 1995-2010. Stroke. 2013 Jan;44(1):138-45. doi: 10.1161/STROKEAHA.112.670844. Epub 2012 Nov 13.
9. Rasquin SM, Verhey FR, van Oostenbrugge RJ, et al. Demographic and CT scan features related to cognitive impairment in the rst year after stroke. J Neurol Neurosurg Psychiatry. 2004 Nov;75(11):1562-7.
10. Ihle-Hansen H, Thommessen B, Wyller TB, et al. Incidence and subtypes of MCI and dementia 1 year after rst-ever stroke in patients without pre-existing cognitive impairment. Dement Geriatr Cogn Disord. 2011;32(6):401-7. doi: 10.1159/000335361. Epub 2012 Feb 3.
11. Jacquin A, Binquet C, Rouaud O, et al. Post-stroke cognitive impairment: high prevalence and determining factors in a cohort of mild stroke. J Alzheimers Dis. 2014;40(4): 1029-38. doi: 10.3233/JAD-131580.
12. Sachdev PS, Brodaty H, Valenzuela MJ, et al. Clinical determinants of dementia and mild cognitive impairment following ischaemic stroke: the Sydney Stroke Study. Dement Geriatr Cogn Disord. 2006;21(5-6):275-83. Epub 2006 Feb 10.
13. Srikanth VK, Anderson JF, Donnan GA, et al. Progressive dementia after first-ever stroke: a community-based follow-up study. Neurology. 2004 Sep 14;63(5):785-92.
14. Srikanth VK, Thrift AG, Saling MM, et al. Increased risk of cognitive impairment 3 months after mild to moderate rst-ever stroke: a Community-Based Prospective Study of Nonaphasic English-Speaking Survivors. Stroke. 2003 May;34(5):1136-43. Epub 2003 Apr 17.
15. Ivan CS, Seshadri S, Beiser A, et al. Dementia after stroke: the Framingham Study. Stroke. 2004 Jun;35(6):1264-8. Epub 2004 Apr 29.
16. Lisabeth LD, Sanchez BN, Baek J, et al. Neurological, functional, and cognitive stroke outcomes in Mexican Americans. Stroke. 2014 Apr;45(4):1096-101. doi: 10.1161/STROKEAHA. 113.003912. Epub 2014 Mar 13.
17. Chausson N, Olindo S, Cabre P, et al. Fiveyear outcome of a stroke cohort in Martinique, French West Indies: Etude Realisee en Martinique et Centree sur l’Incidence des Accidents vasculaires cerebraux, Part 2. Stroke. 2010 Apr;41(4):594-9. doi: 10.1161/STROKEAHA.109.573402. Epub 2010 Feb 18.
18. Yu KH, Cho SJ, Oh MS, et al. Cognitive impairment evaluated with Vascular Cognitive Impairment Harmonization Standards in a multicenter prospective stroke cohort in Korea. Stroke. 2013 Mar;44(3):786-8. doi: 10.1161/STROKEAHA.112.668343. Epub 2012 Dec 27.
19. Tham W, Auchus AP, Thong M, et al. Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci. 2002 Nov 15;203-204:49-52.
20. Das S, Paul N, Hazra A, et al. Cognitive dysfunction in stroke survivors: a communitybased prospective study from Kolkata, India. J Stroke Cerebrovasc Dis. 2013 Nov;22(8): 1233-42. doi: 10.1016/j.jstrokecerebrovasdis.2012.03.008. Epub 2012 Jun 19.
21. Tang WK, Chan SS, Chiu HF, et al. Frequency and clinical determinants of poststroke cognitive impairment in nondemented stroke patients. J Geriatr Psychiatry Neurol. 2006 Jun;19(2):65-71.
22. Zhou DH, Wang JY, Li J, et al. Frequency and risk factors of vascular cognitive impairment three months after ischemic stroke in china: the Chongqing stroke study. Neuroepidemiology. 2005;24(1-2):87-95. Epub 2004 Sep 23.
23. Tu Q, Ding B, Yang X, et al. The current situation on vascular cognitive impairment after ischemic stroke in Changsha. Arch Gerontol Geriatr. 2014 Mar-Apr;58(2):236-47. doi: 10.1016/j.archger.2013.09.006. Epub 2013 Oct 6.
24. Gusev EI, Bogolepova AN. Kognitivnye narusheniya pri tserebrovaskulyarnykh zabolevaniyakh [Cognitive impairments in cerebrovascular diseases]. Moscow: MEDpress-inform; 2013. 160 p.
25. Rist PM, Chalmers J, Arima H, et al. Baseline cognitive function, recurrent stroke, and risk of dementia in patients with stroke. Stroke. 2013 Jul;44(7):1790-5. doi: 10.1161/STROKEAHA.111.680728. Epub 2013 May 16.
26. Parfenov VA. Arterial hypertension and stroke. Nevrologicheskii zhurnal. 2001;(6): 4–7. (In Russ.).
27. Gorelick PB, Scuteri A, Black SE, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/ american stroke association. Stroke. 2011 Sep; 42(9):2672-713. doi: 10.1161/STR.0b013e3182299496. Epub 2011 Jul 21.
28. Shakhparonova NV, Kadykov AS. Neuroprotective therapy in the rehabilitation of patients with post-stroke cognitive impairment and in the prevention of dementia in chronic vascular brain diseases. Atmosfera. Nervnye bolezni. 2011;(1):23–6. (In Russ.).
29. Elbaz A, Vicente-Vytopilova P, Tavernier B, et al. Motor function in the elderly: evidence for the reserve hypothesis. Neurology. 2013 Jul 30;81(5):417-26. doi: 10.1212/WNL.0b013e31829d8761. Epub 2013 Jun 26.
30. Wu Y, Wang M, Ren M, et al. The effects of educational background on Montreal Cognitive Assessment screening for vascular cognitive impairment, no dementia, caused by ischemic stroke. J Clin Neurosci. 2013 Oct;20(10): 1406-10. doi: 10.1016/j.jocn.2012.11.019. Epub 2013 Jul 24.
31. Singh-Manoux A, Marmot MG, Glymour M, et al. Does cognitive reserve shape cognitive decline? Ann Neurol. 2011 Aug;70(2): 296-304. doi: 10.1002/ana.22391. Epub 2011 May 11.
32. Sahathevan R, Brodtmann A, Donnan GA. Dementia, stroke, and vascular risk factors; a review. Int J Stroke. 2012 Jan;7(1):61-73. doi: 10.1111/j.1747-4949.2011.00731.x.
33. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with prestroke and post-stroke dementia: a systematic review and meta-analysis. Lancet Neurol. 2009 Nov;8(11):1006-18. doi: 10.1016/S14744422(09)70236-4. Epub 2009 Sep 24.
34. Sibolt G, Curtze S, Melkas S, et al. Poststroke dementia is associated with recurrent ischaemic stroke. J Neurol Neurosurg Psychiatry. 2013 Jul;84(7):722-6. doi: 10.1136/jnnp-2012-304084. Epub 2013 Feb 16.
35. Erkinjuntti T. Cerebrovascular Dementia: Pathophysiology, Diagnosis and Treatment. CNS Drugs. 1999;12:35-48.
36. Desmond DW, Moroney JT, Paik MC, et al. Frequency and clinical determinants of dementia after ischemic stroke. Neurology. 2000 Mar 14;54(5):1124-31.
37. Jellinger KA. The enigma of mixed dementia. Alzheimers Dement. 2007 Jan;3(1):40-53. doi: 10.1016/j.jalz.2006.09.002.
38. Sun JH, Tan L, Yu JT. Post-stroke cognitive impairment: epidemiology, mechanisms and management. Ann Transl Med. 2014 Aug;2(8): 80. doi: 10.3978/j.issn.2305-5839.2014.08.05.
39. Nys GM, van Zandvoort MJ, de Kort PL, et al. Restrictions of the Mini-Mental State Examination in acute stroke. Arch Clin Neuropsychol. 2005 Jul;20(5):623-9.
40. Roman GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies: report of the NINDS-AIREN International Work Group. Neurology. 1993 Feb; 43(2):250-60.
41. Palmer K, Wang HX, Bä ckman L, et al. Differential evolution of cognitive impairment in nondemented older persons. Am J Psychiatry. 2002 Mar;159(3):436-42.
42. Zakharov VV, Yakhno NN. Syndrome of moderate cognitive impairment in the elderly – diagnosis and treatment. Russkii meditsinskii zhurnal. 2004;(10):573–6. (In Russ.).
43. Reis JP, Loria CM, Launer LJ, et al. Cardiovascular health through young adulthood and cognitive functioning in midlife. Ann Neurol. 2013 Feb;73(2):170-9. doi: 10.1002/ana.23836. Epub 2013 Feb 26.
44. Haag MD, Hofman A, Koudstaal PJ, et al. Duration of antihypertensive drug use and risk of dementia: A prospective cohort study. Neurology. 2009 May 19;72(20):1727-34. doi: 10.1212/01.wnl. 0000345062.86148.3f. Epub 2009 Feb 18.
45. Birks J, Craig D. Galantamine for vascular cognitive impairment. Cochrane Database Syst Rev. 2006 Jan 25;(4):CD004746. doi: 10.1002/14651858.CD004746.pub2.
46. Rockwood K, Mitnitski A, Black SE, et al. Cognitive change in donepezil treated patients with vascular or mixed dementia. Can J Neurol Sci. 2013 Jul;40(4):564-71.
47. Ballard C, Sauter M, Scheltens P, et al. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. Curr Med Res Opin. 2008 Sep;24(9):2561-74. doi: 10.1185/03007990802328142 . Epub 2008 Jul 31.
48. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003154.
49. Baskys A, Cheng JX. Pharmacological prevention and treatment of vascular dementia: approaches and perspectives. Exp Gerontol. 2012 Nov;47(11):887-91. doi: 10.1016/j.exger.2012. 07.002. Epub 2012 Jul 13.
50. Parfenov VA. Distsirkulyatornaya entsefalopatiya i sosudistye kognitivnye rasstroistva [Dyscirculatory encephalopathy and vascular cognitive disorders]. Moscow: IMA-PRESS; 2017. 128 p..
51. Li WZ, Wu WY, Huang H, et al. Protective effect of bilobalide on learning and memory impairment in rats with vascular dementia. Mol Med Rep. 2013 Sep;8(3):935-41. doi: 10.3892/mmr.2013.1573. Epub 2013 Jul 8.
52. Wang BS, Wang H, Song YY, et al. Effectiveness of standardized ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: a bivariate random effect meta-analysis. Pharmacopsychiatry. 2010 May;43(3):86-91. doi: 10.1055/s-0029-1242817. Epub 2010 Jan 26.
53. Weinmann S, Roll S, Schwarzbach C, et al. Effects of Ginkgo biloba in dementia: systematic review and metaanalysis. BMC Geriatr. 2010 Mar 17;10:14. doi: 10.1186/1471-2318-10-14.
54. Ihl R, Tribanek M, Bachinskaya N, et al. Ef cacy and tolerability of a once daily formulation of Ginkgo biloba extract EGb 761(R) in Alzheimer's disease and vascular dementia: results from a randomised controlled trial. Pharmacopsychiatry. 2012 Mar;45(2):41-6. doi: 10.1055/s-0031-1291217. Epub 2011 Nov 15.
55. Zhang SJ, Xue ZY. Effect of Western medicine therapy assisted by Ginkgo biloba tablet on vascular cognitive impairment of none dementia. Asian Pac J Trop Med. 2012 Aug;5(8):661-4. doi: 10.1016/S1995-7645(12)60135-7.
56. Zhang HF, Huang LB, Zhong YB, et al. An Overview of Systematic Reviews of Ginkgo biloba Extracts for Mild Cognitive Impairment and Dementia. Front Aging Neurosci. 2016 Dec 6; 8:276. doi: 10.3389/fnagi.2016.00276. eCollection 2016.
57. Parfenov VA, Verbitskaya SV. Secondary prevention of ischemic stroke and cognitive impairment. Meditsinskii sovet. 2016;(11):18-24. (In Russ.).
58. Parfenov VA, Starchina YuA. Cognitive disorders and their treatment in arterial hypertension. Nervnye bolezni. 2015;(1): 16-22. (In Russ.).
Review
For citations:
Golovacheva V.A., Golovacheva A.A. Poststroke cognitive impairment: diagnosis and treatment. Neurology, Neuropsychiatry, Psychosomatics. 2018;10(2):88-94. (In Russ.) https://doi.org/10.14412/2074-2711-2018-2-88-94